UPDATE 2-Teva, Intel to develop wearable tech for Huntington's disease

Thu Sep 15, 2016 12:14pm EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article | Single Page
[-] Text [+]

(Adds details)

Sept 15 (Reuters) - Teva Pharmaceutical Industries Ltd said on Thursday it was collaborating with Intel Corp to develop a wearable technology platform to track the progression of disease in patients with Huntington's, a fatal degenerative disorder.

The inherited condition causes the progressive breakdown of nerve cells in the brain, resulting in a gradual decline in motor control, cognition and mental stability.

There are no approved drugs to alter the course of Huntington's, although there are medicines that help with symptoms. Patients typically succumb to the disease within 1525 years of diagnosis.

Teva, with Intel, will deploy the technology as part of an ongoing mid-stage Huntington's study, the Israeli company said on Thursday.

Patients will use a smartphone and wear a smartwatch equipped with sensing technology that will continuously measure functioning and movement.

The data from the devices will then be wirelessly streamed to a cloud-based platform, developed by Intel, that will translate it, in near real-time, into scores to assess motor symptom severity.

The line between pharmaceuticals and technology is blurring as companies join forces to tackle chronic diseases using high-tech devices that combine biology, software and hardware.

Accurate monitoring using wearables is expected to dovetail with a drive to offer so-called value-based healthcare.   Continued...